LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! We’re approaching the end of a very interesting year, full of clinical trials and progress. Even today, here are some clinical and preclinical studies with strong potential. Stay strong and fight on! As usual, we also have a podcast […]
TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]
A study presented at the 2025 Society of Urologic Oncology (SUO) Annual Meeting has introduced PROSTest, a novel blood-based mRNA assay that accurately predicts treatment outcomes for 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients. The multi-center investigation analyzed 268 PET-positive mCRPC patients from centers in Munster, Basel, and Essen, all with median […]
Relugolix showed less coronary plaque progression than leuprolide in men receiving androgen deprivation therapy with prostate cancer and pelvic radiotherapy, according to the REVELUTION trial. The prospective study enrolled 94 ADT-naïve men from June 2022 to March 2024, with 90 completing analysis across three arms: radiotherapy alone (n=28), radiotherapy plus leuprolide (n=31), and radiotherapy plus […]
A new form of cell death called triaptosis is starting to attract attention as a potential way to treat hard‑to‑kill cancers. The idea behind it is quite simple: instead of trying to push tumor cells into the classic death routes that many of them have already learned to escape, triaptosis hits them somewhere they are […]
Insilico Medicine has nominated ISM3830, a potentially best-in-class oral CBLB inhibitor discovered through its proprietary Chemistry42 AI platform, as a preclinical candidate for advanced cancer immunotherapy. This novel molecule targets Casitas B-lineage lymphoma-b (CBLB), an intracellular E3 ubiquitin ligase that acts as a master negative regulator of T-cell and natural killer (NK) cell activation, distinct […]
ITC-6146RO is an experimental cancer drug belonging to the class of antibody–drug conjugates, or ADCs. It received IND Approval from Korean Ministry of Food and Drug Safety (Following U.S. FDA) to start a first‑in‑human Phase 1 trial in people with advanced or metastatic solid tumors who no longer respond to standard therapies. It has been […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week we have six interesting clinical trials. I’ve had a very busy week (one of my dogs is seriously ill and I’ve been at the vet very often!) and the preclinical research I managed to read is very […]
MK-6070 is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the body. […]
We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer. Recent regulatory approvals were granted by the U.S. FDA […]